High telomerase activity in granulocytes from clonal polycythemia vera and essential thrombocythemia

Blood

Volumn 105, Issue 5, 2005, Pages 2138-2140

  Ferraris, Anna Maria ^a,b   Mangerini, Rosa ^a   Pujic, Natalija ^a   Racchi, Omar ^a   Rapezzi, Davide ^a   Gallamini, Andrea ^a   Casciaro, Salvatore ^a   Gaetani, Gian Franco ^a  

^a S CROCE E CARLE HOSPITAL   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

TELOMERASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; CLONAL VARIATION; CORRELATION ANALYSIS; ENZYME ACTIVITY; FEMALE; GENE INACTIVATION; GENETIC HETEROGENEITY; GENETIC TRANSFORMATION; GRANULOCYTE; HEMATOPOIESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MONONUCLEAR CELL; MULTIPOTENT STEM CELL; NEUTROPHIL; POLYCYTHEMIA VERA; PRIORITY JOURNAL; THROMBOCYTHEMIA; X CHROMOSOME; CELL CLONE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; CLONE CELLS; DOSAGE COMPENSATION, GENETIC; FEMALE; GRANULOCYTES; HUMANS; LEUKOCYTES, MONONUCLEAR; MIDDLE AGED; POLYCYTHEMIA VERA; PROGNOSIS; TELOMERASE; THROMBOCYTHEMIA, HEMORRHAGIC; TUMOR MARKERS, BIOLOGICAL;

EID: 14944381162     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-06-2375     Document Type: Article

References (24)

1. Blackburn EH. Structure and function of telomere. Nature. 1991;350:569-573.
2. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266:2011-2015.
3. Broccoli D, Young JW, de Lange T. Telomerase activity in normal and malignant hematopoietic cells. Proc Natl Acad Sci U S A. 1995;92:9082-9086.
4. Ohyashiki JH, Sashida G, Tauchi T, Ohyashiki K. Telomeres and telomerase in hematologic neoplasia. Oncogene. 2002;21:680-687.
5. Engelhardt M, Mackenzie K, Drullinsky P, Silver RT, Moore MA. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture. Cancer Res. 2000;60:610-617.
6. Terasaki Y, Okumura H, Ohtake S, Nakao S. Accelerated telomere length shortening in granulocytes: a diagnostic marker for myeloproliferative diseases. Exp Hematol. 2002;30:1399-1404.
7. El Kassar N, Hetet G, Li Y, Briere J, Grandchamp B. Clonal analysis of haemopoietic cells in essential thrombocythaemia. Br J Haematol. 1995;90:131-137.
8. Ferraris AM, Mangerini R, Racchi O, et al. Heterogeneity of clonal development in chronic myeloproliferative disorders. Am J Hematol. 1999;60:158-160.
9. Gilliland DG, Blanchard KL, Levy J, Perrin S, Bunn HF. Clonality in myeloproliferative disorders: analysis by means of the polymerase chain reaction. Proc Natl Acad Sci U S A. 1991;88:6848-6852.
10. Murphy S, Hand H, Rosenthal DS, Laszlo J. Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group. Semin Hematol 1986;23:177-182.
11. Racchi O, Mangerini R, Rapezzi D, Rolfo M, Gaetani GF, Ferraris AM. X chromosome inactivation patterns in normal females. Blood Cells Mol Dis. 1998;24:439-447.
12. Ohyashiki JH, Ohyashiki K, Iwama H. Hayashi S, Toyama K, Shay JW. Clinical implications of telomerase activity levels in acute leukemia. Clin Cancer Res. 1997;3:619-625.
13. Gale RE, Mein CA, Linch DC. Quantification of X-chromosome inactivation patterns in haematological samples using the DNA PCR-based HUMARA assay. Leukemia. 1996;10:362-367.
14. Liu E, Jelinek J, Pastore YD, Guan Y, Prchal JF, Prchal JT. Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin. Blood. 2003;101:3294-3301.
15. Kralovics R, Stockton DW, Prchal JT. Clonal nematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. Blood. 2003;102:3793-3796.
16. Karasawa M, Tsukamoto N, Yamane A, et al. Analysis of the distribution of CAG repeats and X-chromosome inactivation status of HUMARA gene in healthy female subjects using improved fluorescence-based assay. Int J Hematol. 2001;74:281-286.
17. D'Adda T, Candidus S, Denk H, Bordi C, Hofler H. Gastric neuroendocrine neoplasms: tumour clonality and malignancy-associated large X-chromosomal deletions. J Pathol. 1999;189:394-401.
18. Klippel S, Strunck E, Temerinac S, et al. Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis. Blood. 2003;102:3569-3574.
19. Florensa L, Besses C, Zamora L, et al. Endogenous erythroid and megakaryocytic circulating progenitors, HUMARA clonality assay, and PRV-1 expression are useful tools for diagnosis of polycythemia vera and essential thrombocythemia. Blood. 2004;103:2427-2428.
20. Streiff MB, Smith B, Spivak JL. The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of American Society of Hematology members' practice patterns. Blood. 2002;99:1144-1149.
21. Shin LY, Lin TL, Lai CL, et al. Predictive values of X-chromosome inactivation patterns and clinico-hematologic parameters for vascular complications in female patients with essential thrombocythemia. Blood. 2002;100:1596-1601.
22. Fenaux P, Simon M, Caulier MT, Lai JL, Goudemand J, Bauters F. Clinical course of essential thrombocythemia in 147 cases. Cancer. 1990;66:549-556.
23. Harrison CN, Gale RE, Machin SJ, Linch DC. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood. 1999;93:417-424.
24. Shay JW, Wright WE. Telomerase: a target for cancer therapeutics. Cancer Cell. 2002;2:257-265.